Applied Clinical Trials-06-01-2023

Jim Kremidas, former executive director, Association of Clinical Research Professionals, shares his experiences as a patient in clinical trials.

Applying elements from the Fogg Behavioral Model to ease trial complexity.

Best practices in data re-identification and control when designing future trials.

Study uncovers realistic goals in efforts to embrace decentralized clinical trials.

Experts explore potential paths to achieving buy-in from pharma and regulators.

Newly released book edited by Matt Reaney, (PhD, CPsychol, CSci, MSc), head, science and analytics, PCS, at IQVIA focuses on patient experience data with all levels of clinical research in mind.

Since electronic data collection started to gain traction in the 1990s, terminology has evolved and is in need of greater clarity.

In this Q&A, Ashley Moultrie, director of diversity, equity, and inclusion and community engagement for Javara shares her thoughts on current progress and remaining roadblocks in employing effective DEI strategies in clinical research.

Metric derived from CluePoints central monitoring platform assesses average total cycle time from risk signal creation until closure.

Insights from KOLs at the mid-May CRAACO event.

A look at the clinical trials side of oncology.

EU’s sweeping push for major pharma reforms to impact the daily practice of clinical trials community.

Harmonization and value insights are fundamental to bring eConsent to the place it deserves.

Agency seeks added resources and new approaches to accelerate more of these promising treatments to the market.

Complicated process of consenting ICU patients can be simplified with a well-designed eConsent platform.